Global Fund Replenishment Gains Momentum

The call for adequate funding to tackle HIV, tuberculosis and malaria will culminate at next week’s Global Fund replenishment meeting. latest report It claims to have saved 50 million lives between 2002 and 2021.

The Global Fund raises in three-year cycles, seeking $18 billion for its seventh capital increase, culminating in a conference hosted by President Joe Biden on September 19th. With this money, he will save an additional 20 million people.

working together @ Global Fund This partnership has saved 50 million lives since 2002. This proves that global commitment and community leadership can reverse the world’s deadliest infectious disease. #FightForWhatCounts https://t.co/bD9xHDtcPP pic.twitter.com/rbzFfrzglg

— Global Fund (@GlobalFund) September 13, 2022

Since its inception, 23.3 million people living with HIV have received antiretroviral therapy, 5.3 million have received tuberculosis treatment and 133 million mosquito nets have been placed in areas with high malaria prevalence, according to a report released on Monday. was distributed to

In 2010, only 23% of people in need were receiving ART, by the end of 2021 this had increased to 75%.

However, COVID-19 has set back many global goals. Especially tuberculosis treatmentIn 2020, tuberculosis deaths increased for the first time in a decade.

“In 2020, for the first time in our history, our leading program outcomes decreased across all three diseases.” according to to the global fund. “COVID-19 is just eight years away, and he has fallen even further from the Sustainable Development Goal (SDG) goal of ending three epidemics by 2030.”

TB and HIV interventions are beginning to improve, with more people being tested and treated. Global Fund grantees are launching “catch-up” efforts to find and treat people who were not treated during the pandemic.

Pharmaceutical support for the Global Fund

Meanwhile, the International Federation of Pharmaceutical Manufacturers’ Associations (IFPMA) reaffirmed its “longstanding commitment” to support the Global Fund on Tuesday.

“Without further delay, I would like to call upon the Global Fund as a recipe for progressing towards the goal of eliminating and controlling the three most deadly through a combination of human ingenuity, strategic investment and cross-sectoral partnerships. We need to recommit ourselves to a remarkable and proven vision, said IFPMA Executive Director Thomas Cueni.

“From the introduction of new classes of ART, to the development of new tuberculosis diagnostics, to the launch of the first-ever malaria vaccine in 2021, the biopharmaceutical industry has a key role to play in advancing the fight against HIV, tuberculosis and malaria. I’ve done it,” he added. “Pharmaceutical companies continue to pursue research and development, and are now exploring the possibility that vaccine breakthroughs achieved during COVID-19, such as mRNA technology, may offer new hope for the response to the disease.”

IFPMA describes the fund as “an exemplary model of public-private partnership”. report It is “for research and development, capacity building, public awareness and community engagement to improve the global health outcomes associated with the three diseases while defeating the consequences caused by COVID-19.” It emphasizes the role of innovative partnerships.”

Germany pledges a further 30% contribution to the Global Fund

Last week, Germany’s Development Minister Svenja Schulze announced a €1.3 billion commitment to the German fund.

“Each year these diseases infect and kill countless people,” Schulze said. “The good news is that there are ways to treat and prevent diseases. If we act in solidarity, we can end these epidemics. is.”

Germany’s major pledges have increased by 30% compared to the previous three years.

The Children’s Investment Fund Foundation (CIFF) pledged $33 million to the fund last week.

Image credit: Jordi Luis Sirella/IAS.